Novo Nordisk’s statutory Annual Report 2024, Form 20-F, any quarterly financial reports, investor presentations and written information released, shown, or oral statements made, to the public …

1 day ago · We will announce our full-year and fourth quarter results on Wednesday 5 February. On 5 February 2025 at 07:30 CET, we will publish our financial results for the full year of 2024, …

1 day ago · Novo Nordisk (NVO) earnings Q4, full-year FY24 - CNBC

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes and Obesity care products. ... NVO’s Q4 Results in Detail. Novo …

1 day ago · Novo Nordisk was the first-mover in an obesity drug market that some analysts forecast could be worth about $150 billion by the early 2030s, but is now facing fierce …

16 hours ago · Novo Nordisk (NVO 4.70%) Q4 2024 Earnings Call Feb 05, 2025, 7:00 a.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: …

17 hours ago · Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes and Obesity care products. NVO Q4 Earnings Beat …

1 day ago · Zinger Key Points. Novo Nordisk Q4 sales rose 30% to around $12 billion. GLP-1 diabetes sales grew 12% to DKK42.2 billion, while obesity drug sales surged 91% to DKK 21.4 …

• Novo Nordisk continues to be the global market leader in the GLP-1 segment with a 54.8% value market share • Estimated global GLP-1 share of total diabetes

Novo Nordisk A/S NVO reported fourth-quarter 2023 earnings of 71 cents per American Depositary Receipt (ADR), which surpassed the Zacks Consensus Estimate of 66 cents. The …